A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Clinical trial NCT07071337 · RECRUITING
Trial details
- NCT number
- NCT07071337
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-18
- Primary completion
- 2027-07-01
- Enrollment
- 430
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.